135.99
1.28%
-1.77
Neurocrine Biosciences, Inc. stock is currently priced at $135.99, with a 24-hour trading volume of 716.42K.
It has seen a -1.28% decreased in the last 24 hours and a -3.66% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $137.7 pivot point. If it approaches the $134.4 support level, significant changes may occur.
Previous Close:
$137.76
Open:
$137.47
24h Volume:
716.42K
Market Cap:
$13.68B
Revenue:
$1.89B
Net Income/Loss:
$249.70M
P/E Ratio:
73.11
EPS:
1.86
Net Cash Flow:
$361.60M
1W Performance:
+3.02%
1M Performance:
-3.66%
6M Performance:
+26.01%
1Y Performance:
+32.39%
Neurocrine Biosciences, Inc. Stock (NBIX) Company Profile
Name
Neurocrine Biosciences, Inc.
Sector
Phone
858-617-7600
Address
12780 El Camino Real, San Diego, CA
Neurocrine Biosciences, Inc. Stock (NBIX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-23 | Resumed | Citigroup | Neutral |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Aug-21-23 | Reiterated | Mizuho | Neutral |
Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-11-22 | Initiated | UBS | Buy |
Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
Jun-06-22 | Resumed | Jefferies | Buy |
Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
May-18-21 | Resumed | Goldman | Neutral |
May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
Feb-02-21 | Initiated | Raymond James | Outperform |
Sep-30-20 | Initiated | The Benchmark Company | Hold |
Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
Jun-09-20 | Initiated | Wedbush | Outperform |
Mar-06-20 | Initiated | Citigroup | Buy |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Feb-24-20 | Initiated | William Blair | Outperform |
Feb-06-20 | Initiated | Mizuho | Neutral |
Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
Jul-16-19 | Initiated | Oppenheimer | Outperform |
Jun-05-19 | Initiated | Guggenheim | Neutral |
May-21-19 | Initiated | Credit Suisse | Outperform |
Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Feb-06-19 | Reiterated | BofA/Merrill | Buy |
Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-13-18 | Initiated | Goldman | Buy |
Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences, Inc. Stock (NBIX) Latest News
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research
Where Neurocrine Biosciences Stands With Analysts
Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Benzinga
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Benzinga
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Benzinga
Neurocrine Biosciences, Inc. Stock (NBIX) Financials Data
Neurocrine Biosciences, Inc. (NBIX) Revenue 2024
NBIX reported a revenue (TTM) of $1.89 billion for the quarter ending December 31, 2023, a +26.76% rise year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Net Income 2024
NBIX net income (TTM) was $249.70 million for the quarter ending December 31, 2023, a +61.62% increase year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Cash Flow 2024
NBIX recorded a free cash flow (TTM) of $361.60 million for the quarter ending December 31, 2023, a +11.99% increase year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Earnings per Share 2024
NBIX earnings per share (TTM) was $2.42 for the quarter ending December 31, 2023, a +58.17% growth year-over-year.
Neurocrine Biosciences, Inc. Stock (NBIX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BENEVICH ERIC | Chief Commercial Officer |
Apr 15 '24 |
Option Exercise |
81.21 |
19,818 |
1,609,431 |
53,365 |
BENEVICH ERIC | Chief Commercial Officer |
Apr 15 '24 |
Sale |
133.36 |
19,818 |
2,643,020 |
40,778 |
Delaet Ingrid | Chief Regulatory Officer |
Apr 01 '24 |
Option Exercise |
79.02 |
272 |
21,493 |
7,779 |
Delaet Ingrid | Chief Regulatory Officer |
Apr 01 '24 |
Sale |
137.30 |
272 |
37,346 |
7,507 |
Delaet Ingrid | Chief Regulatory Officer |
Mar 21 '24 |
Option Exercise |
103.52 |
5,000 |
517,600 |
12,507 |
Delaet Ingrid | Chief Regulatory Officer |
Mar 21 '24 |
Sale |
145.06 |
5,000 |
725,320 |
7,507 |
BENEVICH ERIC | Chief Commercial Officer |
Mar 14 '24 |
Option Exercise |
80.90 |
75,000 |
6,067,628 |
110,299 |
MORROW GEORGE J | Director |
Mar 14 '24 |
Option Exercise |
39.79 |
40,000 |
1,591,600 |
20,000 |
BENEVICH ERIC | Chief Commercial Officer |
Mar 14 '24 |
Sale |
139.38 |
75,000 |
10,453,417 |
40,778 |
MORROW GEORGE J | Director |
Mar 14 '24 |
Sale |
139.42 |
40,000 |
5,576,710 |
0 |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):